Reference : Management of acute and chronic migraine.
Scientific journals : Article
Human health sciences : Neurology
Management of acute and chronic migraine.
Coppola, G [> > > >]
Schoenen, Jean mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie]
Current Opinion in Supportive and Palliative Care
[en] migraine ; treatment
[en] PURPOSE OF REVIEW: We highlight the recent clinical trials for the management of acute and chronic migraine. RECENT FINDINGS: In women with menstrual migraine, triptans seem to be well tolerated irrespective of whether or not patients are taking oestrogen-containing contraceptives or have comorbidities that indicate increased cardiovascular risk. The new acute drug, telcagepant, a calcitonin gene-related peptide (CGRP) antagonist, is safe for long-term use (up to 18 months) in migraine patients with stable coronary artery disease in whom the use of triptans is not advisable. From the pooled analysis of the two Phase III Research Evaluating Migraine Prophylaxis Therapy studies of onabotulinumtoxinA (BOTOX) in chronic migraineurs, it clearly emerged that efficacy increases overtime (up to 56 weeks) and paralleled self-perceived improvement in quality of life. Effectiveness was also observed in patients with severely disabling headaches, who met criteria for triptan abuse and were refractory to several prophylactic treatments. Finally, combination of preventive pharmacological agents with different action mechanisms may be the next frontier in therapeutic advancements for treating migraine. SUMMARY: Although triptans are safe and well tolerated, CGRP antagonists may be an option for nonresponsive patients or those in whom the use of triptans is not advisable. New drugs and combinations of old therapeutic options may help patients with severe forms of headache.

File(s) associated to this reference

Fulltext file(s):

Open access
Coppola & Schoenen_Management of acute and chronic headaches_1.docxPublisher postprint64.16 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.